Cargando…

Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 1998
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850843/ https://www.ncbi.nlm.nih.gov/pubmed/10505081 http://dx.doi.org/10.1155/1998/698239

Ejemplares similares

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Biomarkers and Surrogate Endpoints: How and When might They Impact Drug Development?
por: Lathia, Chetan D.
Publicado: (2002)

Establishing a Public Resource for Acceptable Surrogate Endpoints to Support FDA Marketing Applications
por: Agyeman, Abena S., et al.
Publicado: (2022)

Cervical Acid Phosphatase: A Biomarker of Cervical Dysplasia and a Potential Surrogate Endpoint for Colposcopy
por: Markovic, Olivera, et al.
Publicado: (2004)

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs
por: Gyawali, Bishal, et al.
Publicado: (2020)

Surrogate endpoints.
por: Ellenberg, S. S.
Publicado: (1993)

Surrogate endpoints in early prostate cancer research
por: Williams, Scott
Publicado: (2018)

Surrogate Endpoints in Medicine
por: Srivastava, Sudhir, et al.
Publicado: (2002)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Immunology careers at the NIH, FDA and CDC: different paths that focus on advancing public health
por: Catalfamo, Marta, et al.
Publicado: (2015)

Surrogate endpoints and competing risk of death in cardiac arrest research
por: McCredie, Victoria A., et al.
Publicado: (2016)

Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
por: Morel, Alix, et al.
Publicado: (2021)

Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints
por: Pitcher, Alex, et al.
Publicado: (2011)

Reply to Commentary by Cummings (2022): Surrogate endpoints extend beyond biomarkers
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017)

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria
por: Jeeyapant, Atthanee, et al.
Publicado: (2017)

Is critical care ready for an economic surrogate endpoint?
por: Wilcox, M Elizabeth, et al.
Publicado: (2015)

Surrogate endpoints… Uncommon for a common man!
por: Kumar, Ashish
Publicado: (2019)

Surrogate Endpoints for Late Kidney Transplantation Failure
por: Naesens, Maarten, et al.
Publicado: (2022)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

Binary surrogate endpoints in clinical trials from the perspective of case definitions
por: HAHN, ANDREAS, et al.
Publicado: (2021)

Translating Basic Research into Clinical Applications: Malaria Research at an NIH Lab
por: Su, Xin-zhuan
Publicado: (2015)

Surrogate Endpoints for Overall Survival in Immune-Oncology Trials of Advanced Gastro-Esophageal Carcinoma
por: Li, Yuan Fang, et al.
Publicado: (2022)

Statistical evaluation of surrogate endpoints: a systematic review
por: Ensor, Hannah, et al.
Publicado: (2013)

Bivariate network meta‐analysis for surrogate endpoint evaluation
por: Bujkiewicz, Sylwia, et al.
Publicado: (2019)

Surrogate endpoints in trials: a call for better reporting
por: Ciani, Oriana, et al.
Publicado: (2022)

Surrogate endpoints in global health research: still searching for killer apps and silver bullets?
por: Pai, Madhukar, et al.
Publicado: (2018)

Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop
por: Nair, Prashant, et al.
Publicado: (2016)

Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening
por: Baker, Stuart G, et al.
Publicado: (2020)

Biomarker changes as surrogate endpoints in early‐phase trials in heart failure with reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2022)

Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
por: Kemp, Robert, et al.
Publicado: (2017)

Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare Cancers
por: Krendyukov, Andriy, et al.
Publicado: (2021)

Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials
por: Chamberlain, Jeffrey S., et al.
Publicado: (2023)

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE
por: Manyara, Anthony Muchai, et al.
Publicado: (2022)

Imputation of a true endpoint from a surrogate: application to a cluster randomized controlled trial with partial information on the true endpoint
por: Nixon, Richard M, et al.
Publicado: (2003)

Uncertainty in the Bayesian meta-analysis of normally distributed surrogate endpoints
por: Bujkiewicz, Sylwia, et al.
Publicado: (2015)

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint
por: Zhang, Zewei, et al.
Publicado: (2023)

Impact of a clinical pharmacist on a cardiovascular surrogate endpoint: a pilot study
por: Ripley, Toni L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_hikrh47m96ps7gsmoihcijlkid